| Casa De La Luz Hospice 7740 North Oracle Road, Tucson, AZ, 85704 | |
| (520) 544-9890 |
News Archive
Each year 3-5 million people have severe cases and 250-500,000 die from complications of seasonal influenza world-wide. This year, the novel 2009 H1N1 (nH1N1) influenza, previously called swine flu, has reached pandemic status.
A new drug with the capacity to reverse vision loss in some patients with age-related macular degeneration (AMD) has won approval from the Food and Drug Administration (FDA) in the U.S.
Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
Patients with addictive disorders who take methadone or other opioid medications for pain will experience heightened sensitivity to pain, known as hyperalgesia, and new research published in The Journal of Pain shows that the condition does not improve over the course of treatment.
› Verified 4 days ago
| Name | Casa De La Luz Hospice |
|---|---|
| Location | 7740 North Oracle Road, Tucson, Arizona |
| Hospice ID | 031547 |
| Category | Freestanding Hospice |
| Ownership Type | Other |
| Profit Type | OTHER |
| SSA county code | 090 |
News Archive
Each year 3-5 million people have severe cases and 250-500,000 die from complications of seasonal influenza world-wide. This year, the novel 2009 H1N1 (nH1N1) influenza, previously called swine flu, has reached pandemic status.
A new drug with the capacity to reverse vision loss in some patients with age-related macular degeneration (AMD) has won approval from the Food and Drug Administration (FDA) in the U.S.
Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
Patients with addictive disorders who take methadone or other opioid medications for pain will experience heightened sensitivity to pain, known as hyperalgesia, and new research published in The Journal of Pain shows that the condition does not improve over the course of treatment.
› Verified 4 days ago
| NPI Number | 1386619799 |
| Organization Name | Casa De La Luz Llc |
| Address | 7740 N Oracle Rd Tucson, Arizona, 85704 |
| Phone Number | (520)544-9890 |
News Archive
Each year 3-5 million people have severe cases and 250-500,000 die from complications of seasonal influenza world-wide. This year, the novel 2009 H1N1 (nH1N1) influenza, previously called swine flu, has reached pandemic status.
A new drug with the capacity to reverse vision loss in some patients with age-related macular degeneration (AMD) has won approval from the Food and Drug Administration (FDA) in the U.S.
Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
Patients with addictive disorders who take methadone or other opioid medications for pain will experience heightened sensitivity to pain, known as hyperalgesia, and new research published in The Journal of Pain shows that the condition does not improve over the course of treatment.
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.8 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 93.9 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 99.7 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 78.3 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 99.2 | 97.3 |
| Patients who got timely treatment for shortness of breath | 96.7 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 94.8 | 93.3 |
News Archive
Each year 3-5 million people have severe cases and 250-500,000 die from complications of seasonal influenza world-wide. This year, the novel 2009 H1N1 (nH1N1) influenza, previously called swine flu, has reached pandemic status.
A new drug with the capacity to reverse vision loss in some patients with age-related macular degeneration (AMD) has won approval from the Food and Drug Administration (FDA) in the U.S.
Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
Patients with addictive disorders who take methadone or other opioid medications for pain will experience heightened sensitivity to pain, known as hyperalgesia, and new research published in The Journal of Pain shows that the condition does not improve over the course of treatment.
› Verified 4 days ago
| Home Health Aides | 27.6 |
| Counselors | 7.8 |
| Licensed Practical or Vocational Nurses | 6.2 |
| Medical Social Workers | 12.2 |
| Physicians | 3.9 |
| Registered Nurses | 65.1 |
| Other Personnel | 77.1 |
| Total Employees | 199.9 |
|---|
News Archive
Each year 3-5 million people have severe cases and 250-500,000 die from complications of seasonal influenza world-wide. This year, the novel 2009 H1N1 (nH1N1) influenza, previously called swine flu, has reached pandemic status.
A new drug with the capacity to reverse vision loss in some patients with age-related macular degeneration (AMD) has won approval from the Food and Drug Administration (FDA) in the U.S.
Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
Patients with addictive disorders who take methadone or other opioid medications for pain will experience heightened sensitivity to pain, known as hyperalgesia, and new research published in The Journal of Pain shows that the condition does not improve over the course of treatment.
› Verified 4 days ago
| Homemakers | 114 |
| Total Volunteers | 114 |
|---|
News Archive
Each year 3-5 million people have severe cases and 250-500,000 die from complications of seasonal influenza world-wide. This year, the novel 2009 H1N1 (nH1N1) influenza, previously called swine flu, has reached pandemic status.
A new drug with the capacity to reverse vision loss in some patients with age-related macular degeneration (AMD) has won approval from the Food and Drug Administration (FDA) in the U.S.
Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
Patients with addictive disorders who take methadone or other opioid medications for pain will experience heightened sensitivity to pain, known as hyperalgesia, and new research published in The Journal of Pain shows that the condition does not improve over the course of treatment.
› Verified 4 days ago
| Amedisys Hospice Location: 5185 East River Road, Suite 201, Tucson, Arizona, 85718 Phone: (520) 544-9890 |
| T M C Hospice Aka Peppi's House Location: 2715 North Wyatt Drive, Tucson, Arizona, 85712 Phone: (520) 544-9890 |
| Hospice Family Care, Inc. - Tucson Location: 6300 East El Dorado Plaza, A-100, Tucson, Arizona, 85715 Phone: (520) 544-9890 |
| Kindred Hospice Location: 5210 East Williams Circle, Suite 100, Tucson, Arizona, 85711 Phone: (520) 544-9890 |